Dr. Martin Tremblay is a passionate and adventurous drug hunter with over seventeen years of experience leading the discovery and development of innovative cancer drugs. Dr. Tremblay has been an intellectual and organizational leader for the discovery and early development of three drug candidates, most notably IPI-549 and IPI-926 (patidegib), which are in Phase II and III clinical development, respectively.
Prior to joining FogPharma, Dr. Tremblay was the Senior Director of Small Molecule Discovery at Tesaro, where he acted as the internal chemistry project lead for the MD Anderson and Evotec collaborations. He also provided small molecule expertise in evaluating and conducting due diligence for several prospective partnership opportunities. Before that, Dr. Tremblay held positions of increasing responsibility at Infinity Pharmaceuticals, where he ultimately served as the Senior Director of Chemistry. There, he led a multidisciplinary discovery team that advanced two isoform selective PI3K inhibitors into IND-enabling studies. Earlier in his career, Dr. Tremblay worked as a Discovery Chemist at Eisai Co., where he synthesized analogs of structurally complex natural products.
Dr. Tremblay earned a B.S. in Biochemistry at Laval University, a M.S. and Ph.D. in Physiology-Endocrinology (Medicinal Chemistry) at Laval University, and was a Postdoctoral Fellow in Chemistry at The Scripps Research Institute.